Vlad Eugen Tiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vlad Eugen Tiu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Alina Flavia Tomescu
Bucharest University Emergency Hospital, Bucharest, Romania
1 shared publicationAndreea Ioana Mușuroi
Bucharest University Emergency Hospital, Bucharest, Romania
1 shared publicationCristina Tiu
Bucharest University Emergency Hospital, Bucharest, Romania
1 shared publicationElena Terecoasă
Bucharest University Emergency Hospital, Bucharest, Romania
1 shared publicationFlorin Dobrițoiu
Bucharest University Emergency Hospital, Bucharest, Romania
1 shared publicationIleana Maria Vodă
Bucharest University Emergency Hospital, Bucharest, Romania
1 shared publication
Latest Publications
- Open Access
- 5 February 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1530438
Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients
Background: Widespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.Methods: We present a critical review of the available literature on diagnosis and management of anti-CD20 induced colitis and display a case series of 3 suspected patients in our cohort.Results: Two patients met the full criteria for ocrelizumab-induced colitis, while a third partially met the criteria. Following symptomatic treatment and discontinuation of ocrelizumab, the patients showed favorable outcomes.Conclusion: Ocrelizumab-induced colitis is a rare, but severe adverse event. Its incidence may be higher than expected, reaching 1,95% in our cohort of MS patients. Further reporting of such cases is essential to broaden our understanding of this side effect.
- 5 February 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1530438
Open AccessOcrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients
Background: Widespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent FDA statement regarding this safety concern. Objectives: We analyzed a cohort of ocrelizumab treated patients in our MS center to evaluate the incidence of drug-induced colitis.Methods: We present a critical review of the available literature on diagnosis and management of anti-CD20 induced colitis and display a case series of 3 suspected patients in our cohort.Results: Two patients met the full criteria for ocrelizumab-induced colitis, while a third partially met the criteria. Following symptomatic treatment and discontinuation of ocrelizumab, the patients showed favorable outcomes.Conclusion: Ocrelizumab-induced colitis is a rare, but severe adverse event. Its incidence may be higher than expected, reaching 1,95% in our cohort of MS patients. Further reporting of such cases is essential to broaden our understanding of this side effect.